Springworks Therapeutics Stock Performance
| SWTX Stock | USD 47.21 2.68 5.37% |
On a scale of 0 to 100, SpringWorks Therapeutics holds a performance score of 7. The entity has a beta of -0.21, which indicates not very significant fluctuations relative to the market. As returns on the market increase, returns on owning SpringWorks Therapeutics are expected to decrease at a much lower rate. During the bear market, SpringWorks Therapeutics is likely to outperform the market. Please check SpringWorks Therapeutics' maximum drawdown, skewness, day typical price, as well as the relationship between the downside variance and daily balance of power , to make a quick decision on whether SpringWorks Therapeutics' existing price patterns will revert.
Risk-Adjusted Performance
OK
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in SpringWorks Therapeutics are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak basic indicators, SpringWorks Therapeutics showed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (2.77) | Five Day Return (3.35) | Year To Date Return 34.45 | Ten Year Return 114.36 | All Time Return 114.36 |
1 | Disposition of 3465 shares by Cassidy James of SpringWorks Therapeutics at 38.19 subject to Rule 16b-3 | 01/03/2025 |
2 | Disposition of 1658 shares by Cassidy James of SpringWorks Therapeutics at 38.86 subject to Rule 16b-3 | 01/06/2025 |
3 | Disposition of 3575 shares by Weinstein Herschel S of SpringWorks Therapeutics at 38.19 subject to Rule 16b-3 | 01/07/2025 |
4 | Merck KGaA pursuing Springworks BridgeBio wins EU drug OK | 02/11/2025 |
5 | Insider Selling SpringWorks Therapeutics, Inc. Director Sells 175,000 Shares of Stock | 02/14/2025 |
6 | SpringWorks Therapeutics Inc Reports Strong 2024 Financial Results and FDA Approval for ... | 02/21/2025 |
7 | Disposition of 30756 shares by Islam Saqib of SpringWorks Therapeutics at 53.41 subject to Rule 16b-3 | 02/27/2025 |
8 | Disposition of 600 shares by Islam Saqib of SpringWorks Therapeutics at 56.89 subject to Rule 16b-3 | 03/03/2025 |
9 | Why SpringWorks Therapeutics Is Skyrocketing So Far in 2025 | 03/04/2025 |
10 | Head to Head Contrast Relay Therapeutics SpringWorks Therapeutics | 03/05/2025 |
11 | Insider Sell Saqib Islam Sells 49,000 Shares of SpringWorks Therapeutics Inc | 03/06/2025 |
12 | SpringWorks Therapeutics Sees Unusually-High Trading Volume - Heres What Happened - MarketBeat | 03/10/2025 |
13 | SpringWorks Therapeutics, Inc.s Shares Climb 26 percent But Its Business Is Yet to Catch Up | 03/12/2025 |
14 | This Is What Whales Are Betting On SpringWorks Therapeutics | 03/18/2025 |
15 | SpringWorks Therapeutics, Inc. Short Interest Update - MarketBeat | 03/20/2025 |
16 | Disposition of 12078 shares by Badreddin Edris of SpringWorks Therapeutics at 54.2582 subject to Rule 16b-3 | 03/21/2025 |
| Begin Period Cash Flow | 176.7 M |
SpringWorks |
SpringWorks Therapeutics Relative Risk vs. Return Landscape
If you would invest 3,714 in SpringWorks Therapeutics on December 25, 2024 and sell it today you would earn a total of 1,007 from holding SpringWorks Therapeutics or generate 27.11% return on investment over 90 days. SpringWorks Therapeutics is currently generating 0.5754% in daily expected returns and assumes 6.2128% risk (volatility on return distribution) over the 90 days horizon. In different words, 55% of stocks are less volatile than SpringWorks, and 89% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
SpringWorks Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for SpringWorks Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as SpringWorks Therapeutics, and traders can use it to determine the average amount a SpringWorks Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0926
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | SWTX | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 6.21 actual daily | 55 55% of assets are less volatile |
Expected Return
| 0.58 actual daily | 11 89% of assets have higher returns |
Risk-Adjusted Return
| 0.09 actual daily | 7 93% of assets perform better |
Based on monthly moving average SpringWorks Therapeutics is performing at about 7% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of SpringWorks Therapeutics by adding it to a well-diversified portfolio.
SpringWorks Therapeutics Fundamentals Growth
SpringWorks Stock prices reflect investors' perceptions of the future prospects and financial health of SpringWorks Therapeutics, and SpringWorks Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on SpringWorks Stock performance.
| Return On Equity | -0.47 | ||||
| Return On Asset | -0.26 | ||||
| Profit Margin | (1.35) % | ||||
| Operating Margin | (1.32) % | ||||
| Current Valuation | 3.44 B | ||||
| Shares Outstanding | 74.94 M | ||||
| Price To Earning | 6.14 X | ||||
| Price To Book | 7.77 X | ||||
| Price To Sales | 18.97 X | ||||
| Revenue | 191.59 M | ||||
| Gross Profit | 179.04 M | ||||
| EBITDA | (278.13 M) | ||||
| Net Income | (258.13 M) | ||||
| Cash And Equivalents | 334.54 M | ||||
| Cash Per Share | 6.81 X | ||||
| Total Debt | 7.91 M | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 9.80 X | ||||
| Book Value Per Share | 6.47 X | ||||
| Cash Flow From Operations | (175.6 M) | ||||
| Earnings Per Share | (3.48) X | ||||
| Market Capitalization | 3.64 B | ||||
| Total Asset | 587.28 M | ||||
| Retained Earnings | (1.15 B) | ||||
| Working Capital | 280.48 M | ||||
| Current Asset | 29.13 M | ||||
| Current Liabilities | 10.16 M | ||||
About SpringWorks Therapeutics Performance
Evaluating SpringWorks Therapeutics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if SpringWorks Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if SpringWorks Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 297.00 | 282.15 | |
| Return On Tangible Assets | (0.45) | (0.47) | |
| Return On Capital Employed | (0.57) | (0.60) | |
| Return On Assets | (0.44) | (0.46) | |
| Return On Equity | (0.54) | (0.51) |
Things to note about SpringWorks Therapeutics performance evaluation
Checking the ongoing alerts about SpringWorks Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for SpringWorks Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| SpringWorks Therapeutics is way too risky over 90 days horizon | |
| SpringWorks Therapeutics appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 191.59 M. Net Loss for the year was (258.13 M) with profit before overhead, payroll, taxes, and interest of 179.04 M. | |
| SpringWorks Therapeutics currently holds about 334.54 M in cash with (175.6 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.81. | |
| SpringWorks Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Over 98.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: SpringWorks Therapeutics, Inc. Short Interest Update - MarketBeat |
- Analyzing SpringWorks Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether SpringWorks Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining SpringWorks Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating SpringWorks Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of SpringWorks Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of SpringWorks Therapeutics' stock. These opinions can provide insight into SpringWorks Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for SpringWorks Stock Analysis
When running SpringWorks Therapeutics' price analysis, check to measure SpringWorks Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SpringWorks Therapeutics is operating at the current time. Most of SpringWorks Therapeutics' value examination focuses on studying past and present price action to predict the probability of SpringWorks Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SpringWorks Therapeutics' price. Additionally, you may evaluate how the addition of SpringWorks Therapeutics to your portfolios can decrease your overall portfolio volatility.